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ABSTRACT  23 
 24 
Brain glycogen is mainly stored in astrocytes. However, recent studies both in vitro and in 25 
vivo indicate that glycogen also plays important roles in neurons. By conditional deletion of 26 
glycogen synthase (GYS1), we previously developed a mouse model entirely devoid of 27 
glycogen in the central nervous system (GYS1Nestin-KO). These mice displayed altered 28 
electrophysiological properties in the hippocampus and increased susceptibility to kainate-29 
induced seizures. To understand which of these functions is related to astrocytic glycogen, 30 
in the present study we generated a mouse model in which glycogen synthesis is eliminated 31 
specifically in astrocytes (GYS1Gfap-KO). Electrophysiological recordings of awake 32 
behaving mice revealed alterations in input/output curves and impaired long-term 33 
potentiation, similar, but to a lesser extent, to those obtained with GYS1Nestin-KO mice. 34 
Surprisingly, GYS1Gfap-KO mice displayed no change in susceptibility to kainate-induced 35 
seizures as determined by fEPSP recordings and video monitoring. These results confirm 36 
the importance of astrocytic glycogen in synaptic plasticity. (150 words) 37 
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1 INTRODUCTION 42 
 43 
Most cell types in the body store glucose in the form of glycogen, a branched 44 
macromolecule containing up to 55,000 glucose units. The only enzyme able to form 45 
glycogen in vivo is glycogen synthase (GYS). There are two isoforms of glycogen synthase 46 
in mammals: the muscle isoform, GYS1, which is expressed in all tissues except the liver, 47 
and the liver-specific isoform, GYS2. In the brain, glycogen is estimated to comprise about 48 
0.1% of tissue weight [1]. Both astrocytes and neurons express GYS1 and synthesize 49 
glycogen, although glycogen levels in astrocytes are much higher than in neurons [2, 3].   50 
In the past decades, numerous studies have demonstrated that brain glycogen plays a 51 
role in memory consolidation and synaptic function [reviewed in [4–6]]. In histological 52 
studies of the healthy brain, glycogen granules are almost always confined to astrocytic cell 53 
bodies and processes [7]. Hence, there is a longstanding belief that the contribution of brain 54 
glycogen to cerebral functions is entirely due to its role in astrocytes. However, recent in 55 
vitro studies suggested an active glycogen metabolism in neurons [2, 8]. 56 
To study the role of brain glycogen in vivo, we previously developed a transgenic 57 
mouse line (GYS1Nestin-KO) which lacked GYS1 and thus glycogen throughout the whole 58 
CNS, while GYS1 expression was normal in other tissues. Paired-pulse recordings at the 59 
CA3-CA1 synapse of the hippocampus showed that the GYS1Nestin-KO animals displayed 60 
increased facilitation, i.e. an increased response to the second pulse [9, 10]. The GYS1Nestin-61 
KO animals also exhibited impaired long-term potentiation (LTP) evoked at the CA3-CA1 62 
synapse. LTP is believed to be a primary molecular mechanism underlying long-term 63 
memory consolidation [9]. Additionally, the animals were more susceptible to hippocampal 64 
seizures induced by kainate or train stimulation [10]. These in vivo results demonstrate that 65 
brain glycogen plays a role in both short- and long-term synaptic plasticity as well as in the 66 
prevention of seizures. 67 
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Since the GYS1Nestin-KO mice lacked both glial and neuronal glycogen, the differential 68 
contribution of each glycogen pool to these results could not be determined with this 69 
model. For this reason, we next generated a new model with greater cellular resolution 70 
devoid of GYS1 in a subset of glutamatergic neurons, the excitatory Ca2+/calmodulin-71 
dependent protein kinase 2 (Camk2a)-positive neurons of the forebrain [11], including the 72 
pyramidal cells of the hippocampal CA3-CA1 synapse. Like the GYS1Nestin-KO, these 73 
animals presented  altered LTP and an associative learning deficiency, although the 74 
impairment was not as pronounced. However, unlike the GYS1Nestin-KO mice, GYS1Camk2a-75 
KO mice exhibited no statistically significant change in PPF and no difference in 76 
susceptibility to kainate-induced seizures. This study corroborated the presence of an active 77 
glycogen metabolism in neurons in vivo and illustrated the importance of neuronal 78 
glycogen in LTP. However, since only a subset of neurons was affected in this model, it 79 
remains unclear whether the differences between the GYS1Nestin-KO and GYS1Camk2a-KO lines 80 
are due to the lack of astrocytic glycogen and/or glycogen in another subtype of neuron. 81 
In the present study, we generated a new mouse model, lacking GYS1 specifically in 82 
astrocytes (GYS1Gfap-KO). Our results clarify the specific contribution of astrocytic glycogen 83 
to cerebral function, confirming its role in synaptic plasticity and discarding its role in the 84 
prevention of epileptic seizures.  85 
 86 
2 METHODS 87 
 88 
2.1 Animals 89 
Male and female mice aged 4 ± 1 months were used in this study. All experiments 90 
were carried out following European Union (2010/63/EU) and Spanish (BOE 34/11370-91 
421, 2013) regulations for the use of laboratory animals. In addition, all experimental 92 
protocols were approved by the Ethics Committee of the Pablo de Olavide University. 93 
Animals were kept in collective cages (up to five animals per cage) on a 12-h light/dark 94 
cycle with constant temperature (21 ± 1°C) and humidity (50 ± 5%). After 95 
electrophysiological studies were initiated, mice were kept in individual cages until the end 96 
of the experiments. Animals were allowed access ad libitum to commercial mouse chow 97 
and water. The Gfap-Cre transgenic line 77.6 used in this study was purchased from 98 
Jackson laboratories (Stock #024098) and has been thoroughly characterized [12].  99 
 100 
2.2 Biochemical analysis 101 
Mice were euthanized by cervical dislocation and decapitation. For total glycogen 102 
measurements, whole brains were dissected and flash frozen in liquid nitrogen. For Western 103 
blots, brains were removed, hemisected, and the cerebellum, hippocampus and cortex from 104 
each hemisphere were dissected and frozen in liquid nitrogen. All samples were maintained 105 
at -80 ºC until use. For glycogen quantifications, whole brains were boiled in 30% KOH for 106 
15 min and glycogen was determined by an amyloglucosidase-based assay as previously 107 
described [2]. Tissue lysates for Western blot were prepared as previously described [11] 108 
and sample protein content was determined by Bradford assay (BioRad). Lysates were 109 
loaded in 10% polyacrylamide gels and transferred to Immobilon membranes (Millipore) 110 
for Western blot. The following antibodies were used: anti-glycogen synthase (Cell 111 
Signaling cat# 3886) and anti-GFAP (Millipore cat# MAB360). The REVERT total protein 112 
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stain was used as a loading control and densitometry was performed using Image StudioTM 113 
Lite (LI-COR BioSciences). 114 
 115 
2.3 In situ hybridization (ISH) and immunolabeling 116 
Mice were anesthetized by intraperitoneal injection of sodium thiopental (Braun) and 117 
perfused transcardially with 4% paraformaldehyde (PFA). Brains were removed, postfixed 118 
overnight in 4% PFA, and embedded in paraffin. Paraffin sections (5 μm in thickness) were 119 
then cut in a microtome. RNAscope Intro Pack 2.5 HD Reagent Kit Red – Mm (cat# 120 
322373, ACD, Biotechne) was used for the detection of the Gys1 (Mus musculus) probe 121 
(cat# 546911, ACD, Biotechne) as specified by the manufacturer with minor modifications.  122 
Sections were dewaxed and pretreatment was done with RNAScope ® Target Retrieval 123 
Reagent for 15 min and with RNAScope Protease Plus for 30 min. Probe incubation was 124 
perfomed for 2h at 40ºC. After Gys1 amplification and signal detection, samples were 125 
blocked with 5 % of normal goat serum (16210064, Thermofisher) mixed with 2.5 % BSA 126 
diluted in wash buffer for and with Mouse on mouse (MOM) Immunodetection Kit – 127 
(BMK-2202, Vector Laboratories). Primary mouse IgG1 anti-GFAP antibody (MAB360, 128 
Merck Millipore) was diluted 1:1000 and incubated overnight at 4ºC. Alexa Fluor 488 Goat 129 
anti-mouse (405319, Biolegend) was used as the secondary antibody. Samples were stained 130 
with DAPI (D9542, Sigma) and mounted with fluorescence mounting medium (S3023 131 
Dako).  132 
Digital scanned fluorescent images were acquired using a NanoZoomer-2.0 HT C9600 133 
scanner (Hamamatsu, Photonics, France) using NDP.scan2.5 software U10074-03 134 
(Hamamatsu, Photonics, France).  135 
 136 
2.4 Animal preparation for the electrophysiological study 137 
For electrode implantation, animals were anesthetized with 0.8–3% halothane from a 138 
calibrated Fluotec 5 (Fluotec-Ohmeda, Tewksbury, MA, USA) delivered via a homemade 139 
mask and vaporizer at a flow rate of 0.8 L/min oxygen. Briefly, animals were implanted 140 
with bipolar stimulating electrodes at the right Schaffer collaterals of the dorsal 141 
hippocampus and with a recording electrode in the ipsilateral CA1 area using stereotaxic 142 
coordinates [13]. Electrodes were made of 50 μm Teflon-coated tungsten wire (Advent 143 
Research Materials Ltd., Eynsham, England). The final location of the CA1 recording 144 
electrode was determined electrophysiologically, as described by some of us [11, 14]. 145 
Stimulating, recording and ground wires were soldered to a 6-pin socket. The socket was 146 
fixed to the skull with the help of three small screws and dental cement [11, 14]. 147 
 148 
2.5 Input/output curves and LTP procedures 149 
 150 
Both input/output curves, paired-pulse facilitation (PPF), and LTP were evoked in 151 
behaving mice following procedures described elsewhere [11, 14]. For the 152 
electrophysiological study, the mouse was located in a small (5 × 5 × 5 cm) box, aimed to 153 
avoid over walking. For input/output curves, mice were stimulated at the CA3-CA1 154 
synapse with single pulses of increasing intensities (0.02–0.4 mA). PPF was determined by 155 
applying double pulses with increasing inter-pulse intervals (10, 20, 40, 100, 200 and 500 156 
ms) at a fixed intensity corresponding to ~40% of asymptotic values, as previously 157 
described [11]. Evoked field excitatory post-synaptic potentials (fEPSPs) were recorded 158 
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with Grass P511 differential amplifiers, across a high impedance probe (2 × 1012 Ω; 10 pF), 159 
and with a bandwidth of 0.1 Hz-10 kHz (Grass-Telefactor, West Warwick, RI, USA).  160 
For LTP measurements, baseline fEPSP values evoked at the CA3-CA1 synapse were 161 
collected 15 min prior to LTP induction using single 100 μs, square, biphasic pulses. Pulse 162 
intensity was set well below the threshold for evoking a population spike (0.15-0.25 mA); 163 
i.e., 30–40% of the intensity necessary for evoking a maximum fEPSP response [14, 15]. 164 
LTP was evoked with a high-frequency stimulus (HFS) protocol consisting of five 200 Hz, 165 
100-ms trains of pulses at a rate of 1/s, repeated six times, at intervals of 1 min. The 166 
stimulus intensity during the HFS protocol was set at the same value as that used for 167 
generating baseline recordings to prevent the presentation of electroencephalographic 168 
seizures and/or large population spikes. After each HFS session, the same stimuli were 169 
presented individually every 20 s for 60 additional min and for 30 min on the following 170 
three days [11, 14]. Evoked fEPSPs were recorded as described above. 171 
 172 
2.6 Induction of hippocampal seizures with kainate injections in implanted mice 173 
 174 
Following procedures described elsewhere [16], we determined the propensity of 175 
control and GYS1Gfap-KO mice to generate convulsive seizures in the hippocampal area. For 176 
this, we intraperitoneally (i.p.) administrated the AMPA/kainate receptor agonist kainate (8 177 
mg/kg; Sigma, St. Louis, MO, USA) dissolved in 0.1 M phosphate buffered saline (PBS) 178 
pH = 7.4. Local field potentials and electrically evoked fEPSPs were recorded in the 179 
hippocampal CA1 area from 5 min before to 60 min after kainate injections. 180 
 181 
2.7 Video monitoring of seizures after kainate injections 182 
Animals were placed in individual cages and were administered with three consecutive 183 
i.p. injections of kainate (8 mg/kg per dose, 24 mg/kg total) one every 30 min from the 184 
onset of the experiment in order to induce convulsive non-lethal seizures. Seizure stages 185 
after kainate injections were evaluated as described previously [17–19]. After the first 186 
kainate injections, the animals developed hypoactivity and immobility (Stage I–II). After 187 
successive injections, hyperactivity (Stage III) and scratching (Stage IV) were often 188 
observed. Some animals progressed to a loss of balance control (Stage V) and further 189 
chronic whole-body convulsions (Stage VI). Extreme behavioural manifestations such as, 190 
uncontrolled hopping activity, or “popcorn behaviour” and continuous seizures (more than 191 
1 minute without body movement control) were included in Stage VI. All behavioural 192 
assessments were performed blind to the experimental group (genotype) in situ, as well as 193 
recorded and reanalysed blind to the first analysis. Analysis consisted in the record of the 194 
time spent until the onset of the first seizure, the number of seizures per animal, the time 195 
spent on each grade, as well as the maximum grade reached by each animal.  196 
 197 
2.8 Data collection and statistical analysis 198 
fEPSPs and 1-V rectangular pulses corresponding to brain stimulation were stored 199 
digitally on a computer through an analog/digital converter (CED 1401 Plus, CED, 200 
Cambridge, England). Data were analyzed off-line for fEPSP recordings with the help of 201 
the Spike 2 (CED) program. Five successive fEPSPs were averaged, and the mean value of 202 
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the amplitude (in mV) was determined. Computed results were processed for statistical 203 
analysis using the IBM SPSS Statistics 18.0 (IBM, Armonk, NY, United States). Data are 204 
represented as the mean ± SEM. Statistical significance of differences between groups was 205 
inferred by Two-way repeated measures ANOVA, followed by the Holm-Sidak method for 206 
all pairwise multiple comparison procedures. The Fisher exact test for data collected from 207 
kainate experiments. Statistical significance was set at P < 0.05. For the biochemical 208 
analyses and behavioral assessment of seizure susceptibility after kainate administration, 209 
computed results were processed for statistical analysis with PRISM 8.0 (GraphPAD 210 
Software, San Diego, USA). Data are represented as the mean ± SEM. Normality of the 211 
distributions was checked via the Shapiro–Wilk test; All tests performed were two-sided. 212 
Statistical significance of differences between groups was inferred by Student’s t-Test or 213 
Two-way ANOVA, followed by the Bonferroni post-hoc comparison for all pairwise 214 
multiple comparison procedures. Statistical significance was set at P < 0.05. 215 
3 RESULTS 216 
3.1 Generation of GYS1Gfap-KO mice 217 
GFAP is a cytoskeletal protein found in nearly all astrocytes and a common marker for 218 
this cell type. The astrocyte-specific inactivation of Gys1 was achieved by crossing mice 219 
homozygous for the conditional Gys1 allele [9] with mice expressing Cre recombinase 220 
under the control of the Gfap promoter [12]. Littermates that were homozygous for the 221 
conditional Gys1 allele and negative for Cre recombinase expression were used as controls. 222 
To confirm the inactivation of Gys1, we measured GYS1 protein levels in cortex, 223 
hippocampus, and cerebellum by Western blot. GYS1 protein was greatly diminished in all 224 
regions (Fig. 1a). Quantification by densitometry showed that GYS1 expression was 225 
reduced by approximately 80% in the cortex and in the hippocampus, and 60% in the 226 
cerebellum (Fig. 1b). Total brain glycogen was decreased by more than 80% (Fig. 1c), 227 
which is consistent with the reduction in GYS1 protein. No changes in GFAP levels were 228 
observed (Fig. 1a, quantification not shown).   229 
To further confirm the specific removal of GYS1 from astrocytes, we visualized Gys1 230 
mRNA using in situ hybridization (ISH) in combination with immunostaining for GFAP. In 231 
hippocampus, where astrocytes can be clearly visualized beside neuronal layers, abundant 232 
Gys1 expression was associated with both astrocytes and neurons of the dentate gyrus of 233 
control mice (Fig. 1d). In the GYS1Gfap-KO animals, Gys1 staining was eliminated from 234 
GFAP-positive cells, while neuronal Gys1 staining was similar to controls. These results 235 
confirm the specific elimination of Gys1 expression from astrocytes, and also illustrate the 236 
abundance of Gys1 expression within neurons of the hippocampus, confirming our previous 237 
results [11]. 238 
 239 
3.2 Electrophysiological alterations at the CA3-CA1 synapse in GYS1Gfap-KO mice 240 
To study the consequences of the lack of astrocytic glycogen on synaptic function, we 241 
performed recordings of input/output curves, PPF and LTP evoked at the CA3-CA1 242 
synapse of the hippocampus (Fig. 2a). In a first experimental step, we examined the 243 
response of CA1 pyramidal neurons to single pulses of increasing intensity (0.02–04 mA) 244 
presented to the ipsilateral Schaffer collaterals. Both control and GYS1Gfap-KO mice 245 
presented similar increases in the amplitude of fEPSPs evoked at CA1 pyramidal neurons 246 
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by the stimuli presented to Shaffer collaterals (Fig. 2b). These two input/output 247 
relationships were best fitted by sigmoid curves (r ≥ 0.9; P ≤ 0.001; not illustrated), 248 
suggesting the normal functioning of the CA3-CA1 synapse in both groups. However, the 249 
experimental group reached lower maximal fEPSP amplitudes than their littermate controls. 250 
No significant differences [Two-way repeated measures ANOVA; F(19,266) = 1.222; P = 251 
0.239] were observed overall between control and GYS1Gfap-KO groups. However, fEPSPs 252 
evoked by three increasing intensities presented significant differences (All pairwise 253 
multiple comparison procedures; P < 0.05). We also performed an analysis of PPF at the 254 
CA3-CA1 synapse by applying double pulses at a fixed intensity with increasing inter-255 
stimulus intervals (10, 20, 40, 100, 200, 500 ms). Both groups displayed facilitation at 20 256 
and 40 ms intervals (Fig. 2c). GYS1Gfap-KO  exhibited no statistical difference in PPF 257 
compared to control animals [Two-way repeated measures ANOVA; F(5,95) = 0.726; P = 258 
0.606].  259 
In a following experimental step, we evoked LTP at the CA3-CA1 synapse of the two 260 
genotypes as an indication of long-term synaptic plasticity. It is well known that the 261 
hippocampus is involved in the acquisition of different types of associative [20, 21] and 262 
non-associative [22, 23] learning tasks and that the CA3-CA1 synapse is often selected for 263 
evoking LTP in behaving mice [14, 24]. For baseline values, animals were stimulated every 264 
20 s for ≥ 15 min at the implanted Schaffer collaterals (Fig. 2d). Afterward, they were 265 
presented with a high frequency stimulus (HFS) protocol. Immediately after the HFS 266 
session, the same single stimulus used to generate baseline records was presented at the 267 
initial rate (3/min) for another 60 min. As illustrated in Fig. 2d, recording sessions were 268 
repeated for three additional days (30 min each). The control group presented a significant 269 
LTP when comparing baseline values with those collected following the HFS session 270 
(Holm-Sidak method, all pairwise multiple comparison procedures; P ≤ 0.041). Although 271 
the amplitude of fEPSPs also increased in GYS1Gfap-KO mice following the HFS session, 272 
only a tendency was presented (P ≥ 0.671) (Fig. 2d). In addition, the amplitude of fEPSPs 273 
evoked in the control group was significantly [Two-way repeated measures ANOVA; 274 
F(32,512) = 6.277; P < 0.001] larger and longer lasting than that evoked in the experimental 275 
group (Fig. 2d). In summary, GYS1Gfap-KO mice display no change in PPF but a 276 
significantly impaired LTP compared to the littermate controls. 277 
 278 
3.3 Seizure susceptibility in GYS1Gfap-KO mice 279 
Kainate is a widely used chemoconvulsant used to study seizure susceptibility in 280 
rodents [25]. We previously demonstrated that mice devoid of cerebral glycogen 281 
(GYS1Nestin-KO) are more susceptible to kainate-induced seizures [10]. To understand the 282 
participation of astrocytic glycogen in seizure susceptibility, we also assessed the response 283 
of GYS1Gfap-KO mice to kainate-induced seizures in the pre-implanted animals. Evoked 284 
seizures in control and GYS1Gfap–KO mice presented similar durations and profiles (Fig. 3a). 285 
Both groups presented a noticeable depression in the amplitude of evoked fEPSP recorded 286 
following a kainate-dependent seizure (Fig. 3b). Overall, there was no difference in the 287 
number of seizures observed per genotype (Fisher exact test; P = 0.657) (Fig. 3c).   288 
To corroborate these results, we employed an alternative seizure assessment protocol in 289 
a new cohort of mice. Mice were given three kainate injections (8 mg/kg, i.p. every 30 min) 290 
and video-recorded for 180 minutes to monitor their behavior (i.e. epileptic events) 291 
following the first injection. Mice from both genotypes reached similar severity stages (Fig. 292 
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4a).  In the majority of the mice of both genotypes, seizures began approximately 15 293 
minutes after the third dose of kainate (P = 0.9501, Student’s t-test; Fig. 4b). There were no 294 
significant differences between groups in the prioritary stage (the behavioral stage in which 295 
an animal spends the most time after kainate administration throughout the duration of the 296 
experiment) (P = 0.5441, Student’s t-test; Fig. 4c) nor the maximum stage (the most severe 297 
stage reached during the experiment) (P = 0.9644, Student’s t-test; Fig. 4d). Furthermore, 298 
there were no significant differences in the time spent per stage (Two-way ANOVA: Stage 299 
factor: P = 0.0007, Genotype factor: P = 0.2370; Fig. 4e) or in the number of seizures per 300 
animal after each injection (Two-way ANOVA: Administration factor: P < 0.0001, 301 
Genotype factor: P = 0.7980; Fig. 4f). These results unequivocally confirmed that 302 
GYS1Gfap-KO animals present a similar seizure susceptibility compared to control 303 
littermates.  304 
 305 
4 DISCUSSION 306 
 307 
In this study, we analyze for the first time the physiological consequences of removing 308 
glycogen specifically from astrocytes by means of transgenic tools. By comparing this 309 
mouse to previous models lacking glycogen in the entire CNS [9, 10] or only in Camk2a-310 
positive excitatory neurons of the forebrain [11], we are able to define the specific 311 
physiological roles of glycogen in astrocytes versus neurons.  312 
Using Cre/Lox technology, we deleted Gys1 in GFAP-positive cells to eliminate only 313 
astrocytic glycogen synthesis. Western blot analyses confirmed a clear reduction in GYS1 314 
protein levels in hippocampus, cortex and cerebellum of GYS1Gfap-KO mice (Fig. 1, a and 315 
b). Total brain glycogen content was also greatly reduced relative to littermate controls 316 
(Fig. 1c). These results are consistent with the well-documented observation that the 317 
majority of brain glycogen is stored in astrocytes, but also point to a remaining significant 318 
fraction of non-astrocytic GYS1 expression and glycogen synthesis, likely in neurons. The 319 
analysis of Gys1 mRNA distribution by ISH validated the astrocyte-specific deletion of 320 
GYS1 in the GYS1Gfap-KO model and also confirmed a significant proportion of Gys1 321 
expression within neurons, in line with our previous results [11] (Fig. 1d). 322 
 323 
We also studied synaptic function in the GYS1Gfap-KO model via stimulation of the 324 
CA3-CA1 synapse in the hippocampus. Input/output curves showed no overall significant 325 
difference between groups, but at some intensities, evoked fEPSPs were statistically higher 326 
in the control group compared to the GYS1Gfap-KO animals, and the latter group reached a 327 
lower maximum fEPSP (Fig. 2b). These results suggest that the absence of astrocytic 328 
glycogen may reduce basal synaptic strength. A similar situation is obtained with inhibitors 329 
of astrocytic glutamate transport, which also reduce basal EPSPs since the accumulation of 330 
glutamate causes presynaptic inhibition [26]. Astrocytes take up synaptic glutamate and 331 
convert it to glutamine for transfer to neurons, where it is recycled into glutamate and 332 
repackaged into synaptic vesicles, a process known as the glutamate/glutamine cycle [27, 333 
28]. Since astrocytic glycogen has been shown to play a role in both glutamate uptake and 334 
recycling [29, 30], the lack of astrocytic glycogen could cause impaired glutamate uptake 335 
leading to presynaptic inhibition and therefore lower synaptic strength. While PPF 336 
experiments with increasing inter-pulse intervals showed significantly greater facilitation in 337 
GYS1Nestin-KO mice [10], in the present study, GYS1Gfap-KO mice only lack astrocytic 338 
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glycogen displayed only a trend toward increased PPF, with no statistical difference (Fig. 339 
2c).  PPF is typically attributed to presynaptic mechanisms such increased [Ca2+] in the 340 
presynaptic terminal [31]. The altered PPF observed in GYS1Nestin-KO mice could be 341 
exclusively neuronal in origin.  342 
We also observed an impairment in hippocampal LTP in GYS1Gfap-KO animals (Fig. 343 
2d). However, the LTP impairment in the GYS1Gfap-KO animals was not as pronounced as 344 
was observed in the GYS1Nestin-KO mice [9]. The present results are reminiscent of those 345 
from the GYS1Camk2a-KO mice, in which LTP was still observed, although it was 346 
significantly impaired [11]. Collectively, these three mouse models demonstrate that both 347 
astrocytic and neuronal glycogen contribute to LTP. Previous studies using 348 
pharmacological agents have shown that astrocytic glycogen is important for long-term, but 349 
not short-term, memory formation [32, 33]. The presence of a normal PPF, a measure of 350 
short-term plasticity, and the major impairment in LTP that we observed in the GYS1Gfap-KO 351 
model are consistent with these observations. 352 
The most surprising result regarding the GYS1Gfap-KO line is its susceptibility to 353 
kainate-induced epilepsy. We previously showed that GYS1Nestin-KO mice were more 354 
susceptible to seizures induced by a single convulsive dose of kainate (8mg/kg, i.p.) [10]. 355 
However, using the same protocol, we detected no statistical difference in the GYS1Gfap-KO 356 
line (Fig. 3). Utilizing a second experimental protocol with three consecutive doses of 357 
kainate (8mg/kg, i.p., every 30 minutes) we found no statistical differences between the 358 
groups in the seizure stages achieved (Fig. 4a), seizure onset (Fig. 4b), prioritary or 359 
maximum stage reached (Fig. 4, c and d), time spent per stage (Fig. 4e) or number of 360 
seizures per animal (Fig. 4f). These results unequivocally show that GYS1Gfap-KO animals 361 
are not more susceptible to kainate than their littermate controls. Altered glycogen 362 
metabolism has been linked to seizures, as reviewed elsewhere [34–37]. A commonly held 363 
view is that altered astrocytic glycogen metabolism induces neuronal excitability via 364 
impaired glutamate and K+ uptake. However, herein we show mice lacking astrocytic 365 
glycogen do not have more kainate-induced seizures. Since GYS1Camk2-KO mice also show 366 
unaltered kainate susceptibility [11], collectively these mouse models suggest that seizure 367 
susceptibility in the GYS1Nestin-KO line is a consequence of the lack of glycogen in another 368 
cell type. Inhibitory neurons play a critical role in suppressing excitability, and their 369 
dysfunction is associated with epilepsy in rodent models and humans [38]. Therefore, our 370 
results suggest that glycogen in inhibitory neurons might be critical for their regulatory 371 
role. This possibility will be addressed in future studies.  372 
In summary, the GYS1Gfap-KO mouse model illustrates the specific contribution of 373 
astrocytic glycogen to the physiological roles of glycogen in the brain, further clarifying 374 
how brain glycogen is involved in memory and epilepsy. Our results confirm that astrocytic 375 
glycogen plays an active role in long-term synaptic plasticity. However, the lack of 376 
astrocytic glycogen does not increase susceptibility to kainate-induced seizures in these 377 
mice. These data point to a role of neuronal glycogen in cerebral functions, most 378 
importantly in the regulation of excitability. A thorough understanding of these processes is 379 
essential for better management and treatment of neurological disorders.  380 
 381 
Figure Legends 382 
 383 
Fig. 1 Analysis of GYS1, GFAP and glycogen levels in GSGfap-KO mice and controls. (a) 384 
Representative Western blot of GYS1 and GFAP protein levels in cortex (Cx), 385 
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hippocampus (Hp) and cerebellum (Cb). REVERT protein stain (Li-COR BioSciences) was 386 
used as a loading control. (b) Quantification of GYS1 and GFAP protein levels by region 387 
normalized to total protein determined by REVERT. (c) Total brain glycogen in control 388 
versus GSGfap-KO animals. All data are expressed as average ±SEM (n = 4-6 per group). 389 
Significant differences were calculated using student’s t-test (∗, P < 0.05; ∗∗∗, P < 0.001; 390 
****, P < 0.0001). (d) GYS1 in situ hybridization (ISH). Gys1 mRNA expression was 391 
visualized via ISH (orange), GFAP protein by immunostaining (green), and nuclei using 392 
DAPI (blue). The dentate gyrus of the hippocampus from control and GYS1Gfap-KO are 393 
shown. Scale bar = 50 μm. 394 
 395 
Fig. 2 Electrophysiological properties of hippocampal synapses in behaving control and 396 
GYS1Gfap-KO mice. (A) Animals were chronically implanted with bipolar stimulating (St.) 397 
electrodes in the right CA3 Schaffer collaterals and with a recording (Rec.) electrode in the 398 
ipsilateral CA1 area. DG, dentate gyrus; Sub., subiculum. (B) Input/output curves of 399 
fEPSPs evoked at the CA3-CA1 synapse via single pulses of increasing intensities (0.02–400 
0.4 mA) in control and GYS1Gfap-KO mice. Although no significant differences [Two-way 401 
repeated measures ANOVA; F(19,266) = 1.222; P = 0.239] were observed between groups, 402 
fEPSPs evoked by three different intensities presented significant differences (All pairwise 403 
multiple comparison procedures; P < 0.05).  (C) Paired-pulse facilitation in control and 404 
GYS1Gfap-KO animals with increasing inter-stimulus intervals. No significant differences 405 
between the two groups were observed [Two-way repeated measures ANOVA; F(5,95) = 406 
1.222; P = 0.606]. (D) LTP evoked at the CA3-CA1 synapse of control and GYS1Gfap-KO 407 
mice following the HFS session. The HFS was presented after 15 min of baseline 408 
recordings, at the time marked by the dashed line. LTP evolution was followed for four 409 
days. At the right are illustrated representative examples of fEPSPs collected from control 410 
and GYS1Gfap-KO mice at the times indicated in the bottom graph. fEPSP amplitudes are 411 
given as a percentage of values measured from baseline recordings, and statistical 412 
differences between control and GYS1Gfap-KO from two-way repeated measures ANOVA 413 
are shown (*, P ≤ 0.01). All data are expressed as average ± SEM (n= 7-9 mice/group). 414 
 415 
Fig. 3 Kainate susceptibility of GYS1Gfap-KO mice compared to controls. (a) Representative 416 
examples of hippocampal seizures evoked in control and GYS1Gfap-KO mice following the 417 
administration of 8 mg/kg i.p. of kainate. (b) Representative examples of fEPSPs evoked 418 
before and immediately after a kainate-evoked seizure. (c) Percentage of control (n = 14) 419 
and GYS1Gfap-KO (n = 9) mice presenting spontaneous seizures at the CA1 area during the 420 
recording period (60 min). No significant differences between groups (Fisher exact test; P 421 
= 0.657) were observed.  422 
 423 
Fig. 4 Comparison of kainate-induced seizure profile in control and GYS1Gfap-KO. 3-4 424 
months old mice were subjected to three kainate injections (8 mg/kg every 30 min) and 425 
epileptic responses were analyzed for 180 minutes after the first injection. (a) Percentage of 426 
mice reaching seizure stages I to VI and kainate-induced mortality. (b) Onset of the 427 
epileptic activity. Student’s t-test (P = 0.9501). (c) Prioritary stage displayed by each 428 
animal during the course of the experiment. Student’s t-test (P = 0.5441). (d) Maximum 429 
stage reached by each animal during the course of the experiment. Student’s t-test (P = 430 
0.9644). (e) Percentage of time spent on each stage during the course of the experiment. 431 
Two-way ANOVA (Stage factor: P = 0.0007; Genotype factor: P = 0.2370). (f) Number of 432 
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seizures experimented per animal divided on time segments after the first, second and third 433 
kainate administrations. Two-way ANOVA (Administration factor: P < 0.0001; Genotype 434 
factor: P = 0.7980). All data are expressed as average ± SEM (n = 6-7 mice/group). 435 
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